Translational potential of thyroid hormone and its analogs

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 506-511

  Arsanjani, Reza ^a,b   McCarren, Madeline ^c   Bahl, Joseph J ^a,b   Goldman, Steven ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Hines VA Pharmacy Benefits Management   (United States)

Author keywords

Heart failure; Hypercholesterolemia; Review; Thyroid hormone; Thyroid hormone analogs

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM; CATECHOLAMINE; CHOLESTEROL; DEXTROTHYROXINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVOTHYROXINE; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PHOSPHOLAMBAN; POTASSIUM; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR ALPHA1; THYROID HORMONE RECEPTOR ALPHA2; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR BETA1; THYROID HORMONE RECEPTOR BETA2; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHOLESTEROL BLOOD LEVEL; CONSENSUS SEQUENCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART RATE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIOTHYRONINE BLOOD LEVEL; LIPID METABOLISM; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; THYROID HORMONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE;

ANIMALS; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CONTRACTILE PROTEINS; DIIODOTHYRONINES; HEART; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; POTASSIUM; PROPIONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THYROID HORMONES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80052796846     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.12.012     Document Type: Review

References (88)

1. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
2. Roger V.L., Weston S.A., Redfield M.M., Hellermann-Homan J.P., Killian J., Yawn B.P., et al. Trends in heart failure incidence and survival in a community-based population. J Am Med Assoc 2004, 292:344-350.
3. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 9(116):1725-1735.
4. Brent G.A., Moore D.D., Larsen P.R. Thyroid hormone regulation of gene expression. Annu Rev Physiol 1991, 53:17-35.
5. Lazar M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993, 14:184-193.
6. Gloss B., Trost S., Bluhm W., Swanson E., Clark R., Winkfein R., et al. Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology 2001, 142:544-550.
7. Lazar M.A., Chin W.W. Nuclear thyroid hormone receptors. J Clin Invest 1990, 86:1777-1782.
8. Wu Y., Koenig R.J. Gene regulation by thyroid hormone. Trends Endocrinol Metab 2000, 11:207-211.
9. Kahaly G.J., Dillmann W.H. Thyroid hormone action in the heart. Endocr Rev 2005, 26:704-728.
10. Kenessey A., Ojamaa K. Ligand-mediated decrease of thyroid hormone receptor-α1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability. Am J Physiol Heart Circ Physiol 2005, 288:H813-H821.
11. Kenessey A., Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 2006, 281:20666-20672.
12. Kenessey A., Sullivan E.A., Ojamaa K. Nuclear localization of protein kinase C-α induces thyroid hormone receptor-α1 expression in the cardiomyocyte. Am J Physiol Heart Circ Physiol 2006, 290:H381-H389.
13. Fazio S., Palmieri E.A., Lombardi G., Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004, 59:31-50.
14. Dillmann W.H. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990, 88:626-630.
15. Kiss E., Jakab G., Kranias E.G., Edes I. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res 1994, 75:245-251.
16. Walker J.D., Crawford F.A., Kato S., Spinal F.G. The novel effects of 3, 5, 3'-triiodo-L-thyronine on myocyte contractile function and beta-adrenergic responsiveness in dilated cardiomyopathy. J Thorac Cardiovasc Surg 1994, 108:672-679.
17. Belakavadi M., Saunders J., Weisleder N., Raghava P.S., Fondell J.D. Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-∝1 and involves targeted covalent histone modifications. Endocrinology 2010, 151:2946-2956.
18. Morkin E. Regulation of myosin heavy chain genes in the heart. Circulation 1993, 87:1451-1460.
19. Korecky B., Zak R., Schwartz K., Aschenbrenner V. Role of thyroid hormone in regulation of isomyosin composition, contractility, and size of heterotopically isotransplanted rat heart. Circ Res 1987, 60:824-830.
20. Alpert N.R., Mulieri L.A. Heat, mechanics and myosin ATPase in normal and hypertrophied heart muscle. Fed Proc 1982, 41:192-198.
21. Dieckman L.J., Solaro R.J. Effect of thyroid status on thin-filament Ca2+ regulation and expression of troponin I in perinatal and adult rat hearts. Circ Res 1990, 67:344-351.
22. Georges L.P., Santangelo R.P., Mackin J.F., Canary J.J. Metabolic effects of propranolol in thyrotoxicosis. I. Nitrogen, calcium, and hydroxyproline. Metabolism 1975, 24:11-21.
23. Coulombe P., Dussault J.H., Walker P. Plasma catecholamine concentrations in hyperthyroidism and hypothyroidism. Metabolism 1976, 25:973-979.
24. Muntz K.H. Autoradiographic characterization of beta-adrenergic receptor subtype in the canine conduction system. Circ Res 1992, 71:51-57.
25. Hammond H.K., White F.C., Buxton I.L., Saltzstein P., Brunton L.L., Longhurst J.C. Increased myocardial beta-receptors and adrenergic responses in hyperthyroid pigs. Am J Physiol 1987, 252:H283-H290.
26. Hohl C.M., Wetzel S., Fertel R.H., Wimsatt D.K., Brierley G.P., Altschuld R.A. Hyperthyroid adult rat cardiomyocytes. I. Nucleotide content, beta- and alpha-adrenoreceptors, and cAMP production. Am J Physiol 1989, 257:C948-C956.
27. Bahouth S.W. Thyroid hormones transcriptionally regulate the beta 1-adrenergic receptor gene in cultured ventricular myocytes. J Biol Chem 1991, 266:15863-15869.
28. Pachucki J., Burmeister L.A., Larsen P.R. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res 1999, 85:498-503.
29. Carvalho-Bianco S.D., Kim B.W., Zhang J.X., Harney J.W., Ribeiro R.S., Gereben B., et al. Chronic cardiac-specific thyrotoxicosis increases myocardial beta-adrenergic responsiveness. Mol Endocrinol 2004, 18:1840-1849.
30. Novitzky D., Cooper D.K., Chaffin J.S., Greer A.E., DeBault L.E., Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation 1990, 49:311-316.
31. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990, 88:631-637.
32. Ojamaa K., Klemperer J.D., Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996, 6:505-512.
33. Klein I., Ojamaa K. Thyroid hormone: targeting the vascular smooth muscle cell. Circ Res 2001, 88:260-261.
34. Park K.W., Dai H.B., Ojamaa K., Lowenstein E., Klein I., Sellke F.W. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997, 85:734-738.
35. Standen N.B., Quayle J.M., Davies N.W., Brayden J.E., Huang Y., Nelson M.T. Hyperpolarizing vasodilators activate ATP-sensitive K+channels in arterial smooth muscle. Science 1989, 245:177-180.
36. Imai T., Hirata Y., Iwashina M., Marumo F. Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology 1995, 136:1544-1548.
37. Diekman M.J., Harms M.P., Endert E., Wieling W., Wiersinga W.M. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol 2001, 144:339-346.
38. Tomanek R.J., Busch T.L. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec 1998, 251:44-49.
39. Tomanek R.J., Doty M.K., Sandra A. Early coronary angiogenesis in response to thyroxine: growth characteristics and upregulation of basic fibroblast growth factor. Circ Res 1998, 82:587-593.
40. Resnick L.M., Laragh J.H. Plasma renin activity in syndromes of thyroid hormone excess and deficiency. Life Sci 1982, 30:585-586.
41. Dzau V.J., Herrmann H.C. Hormonal control of angiotensinogen production. Life Sci 1982, 30:577-584.
42. Kato K., Murakami H., Isozaki O., Tsushima T., Takano K. Serum concentrations of BNP and ANP in patients with thyrotoxicosis. Endocr J 2009, 56:17-27.
43. Ma Y., Freitag P., Zhou J., Brüne B., Frede S., Fandrey J. Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. Am J Physiol Regul Integr Comp Physiol 2004, 287:R600-R607.
44. Biondi B., Palmieri E.A., Fazio S., Cosco C., Nocera M., Saccà L., et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85:4701-4705.
45. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004, 164:1675-1678.
46. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988, 19:15-18.
47. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116:1725.
48. Danzi S., Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003, 5:513-520.
49. Goldman S., Olajos M., Morkin E. Control of cardiac output in thyrotoxic calves: evaluation of changes in the systemic circulation. J Clin Invest 1984, 73:358-365.
50. Dillman W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev 2010, 15:125-132.
51. Duntas L.H. Thyroid disease and lipids. Thyroid 2002, 12:287-293.
52. Razvi S., Ingoe L., Keeka G., Oates C., McMillan C., Weaver J.U. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007, 92:1715-1723.
53. Morkin E., Ladenson P., Goldman S., Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure past, present, and future prospects. J Mol Cell Cardiol 2004, 37:1137-1146.
54. Opasich C., Pacini F., Ambrosino N., Riccardi P.G., Febo O., Ferrari R., et al. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J 1996, 17:1860-1866.
55. Iervasi G., Pingitore A., Landi P., Raciti M., Ripoli A., Scarlattini M., et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003, 107:708-713.
56. Passino C., Pingitore A., Landi P., Fontana M., Zyw L., Clerico A., et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail 2009, 15:35-40.
57. Pingitore A., Landi P., Taddei M.C., Ripoli A., L'Abbate A., Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005, 118:132-136.
58. Hamilton M.A., Stevenson L.W., Luu M., Walden J.A. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990, 16:91-95.
59. Iervasi G., Molinaro S., Landi P., Taddei M.C., Galli E., Mariani F., et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007, 167:1526-1532.
60. Hamilton M.A., Stevenson L.W., Fonarow G.C., Steimle A., Goldhaber J.I., et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998, 81:443-447.
61. Moruzzi P., Doria E., Agostoni P.G., Capacchione V., Sganzerla P. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 1994, 73:374-378.
62. Novitzky D., Fontanet H., Snyder M., Coblio N., Smith D., Parsonnet V. Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery. Cardiology 1996, 87:509-515.
63. Escobar-Morreale H.F., del Rey F.E., Obregón M.J., de Escobar G.M. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 1996, 137:2490-2502.
64. Degens H., Gilde A.J., Lindhout M., Willemsen P.H., Van Der Vusse G.J., Van Bilsen M. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am J Physiol Heart Circ Physiol 2003, 284:H108-H115.
65. Pennock G.D., Milavetz J.J., Raya T.E., Bahl J.J., Goldman S., Morkin E. Identification of simple substituted phenols with thyromimetic activity: cardiac effects of 3, 5-diiodo-4-hydroxypheylpropionic acid. J Pharmacol Exp Ther 1994, 268:216-223.
66. Pennock G.D., Raya T.E., Bahl J.J., Goldman S., Morkin E. Cardiac effects of 3, 5 diiodothyroproprionic acid, a thyroid analog with inotropic selectivity. J Pharmacol Exp Ther 1992, 263:163-169.
67. Pennock G.D., Raya T.E., Bahl J.J., Goldman S., Morkin E. Combination treatment with captopril and the thyroid hormone analog 3, 5 diiodothyroproprionic acid (DITPA): A new approach to improving left ventricular performance in heart failure. Circulation 1993, 88:1289-1298.
68. Mahaffey K., Raya T.E., Pennock G., Morkin E., Goldman S. Ventricular performance and remodeling in rabbits after myocardial infarction: effects of a thyroid hormone analogue. Circulation 1995, 91:794-802.
69. Wang X., Zheng W., Christensen L.P., Tomanek R.J. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 2003, 284:H613-H618.
70. Morkin E., Pennock G., Spooner P.H., Bahl J.J. Underhill Fox K, Goldman S. Pilot studies on the use of 3, 5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology 2002, 97:218-225.
71. Goldman S., McCarren M., Morkin E., Ladenson P.W., Edson R., Warren S., et al. DITPA (3, 5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009, 119:3039-3100.
72. Walton K.W., Campbell D.A., Tonks E.L. The significance of alterations in serum lipids in thyroid dysfunction. I. The relation between serum lipoproteins, carotenoids and vitamin A in hypothyroidism and thyrotoxicosis. Clin Sci 1965, 29:199-215.
73. Walton K.W., Scott P.J., Dykes P.W., Davies J.W. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci 1965, 29:217-238.
74. Abrams J.J., Grundy S.M. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981, 22:323-338.
75. Staels B., Van Tol A., Chan L., Will H.M., Verhoeven G.A., Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low-density lipoprotein receptor in rats. Endocrinology 1990, 127:1145-1152.
76. Salter A.M., Hayashi R., Al-Seeni M., Brown N.F., Bruce J., Sorensen O., et al. Effects of hypothyroidism and high-fat feeding on mRNA concentrations for the low-density lipoprotein receptor and on acyl-CoA:cholesterol acyltransferase activities in rat liver. Biochem J 1991, 276:825-832.
77. Packard C.J., Shepard J., Lindsay G.M., Gaw A., Taskinen M.R. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-b metabolism in hypothyroidism. J Clin Endocrinol Metab 1993, 76:1209-1216.
78. Strisower B., Gofman J.W., Galioni E., Rubinger J.H., O'Brien G.W., Simon A. Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels. J Clin Endocrinol Metab 1955, 15:73-80.
79. Strisower B., Gofman J.W., Galioni E.F., Rubinger J.H., Pouteau J., Guzvich P. Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels. Lancet 1957, 1:120-123.
80. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. J Am Med Ass 1972, 220:996-1008.
81. Young W.F., Gorman C.A., Jiang N.S., Machacek D., Hay I.D. L-Thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin Pharmacol Ther 1984, 36:781-787.
82. Underwood A.H., Emmett J.C., Ellis D., Flynn S.B., Leeson P.D., Benson M., et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986, 324:425-429.
83. Schueler P.A., Schwartz H.L., Strait K.A., Mariash C.N., Oppenheimer J.H. Binding of 3, 5, 3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the α- and β-forms for the acetic acid analog and failure of the human testis and kidney α-2 products to bind to T3. Mol Endocrinol 1990, 4:227-234.
84. Ye L., Li Y.L., Mellstrom K., Mellin C., Bladh L.G., Koehler K., et al. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J Med Chem 2003, 46:1580-1588.
85. Yokoyama N., Walker G.N., Main A.J., Stanto J.L., Morrissey M.M., Boehm C., et al. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J Med Chem 1995, 38:695-707.
86. Strobl W., Chan L., Patsch W. Differential regulation of hepatic apolipoprotein A-I and A-II by thyroid hormone in rat liver. Atherosclerosis 1992, 97:161-170.
87. Ladenson P.W., McCarren M., Morkin E., Edson R.G., Shih M.-C., Warren S.R., et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010, 95:1349-1354.
88. Ladenson P.W., Kristensen J.D., Ridgway E.C., Olsson A.G., Carlsson B., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010, 362:906-916.